Kanjinti

Active Ingredient(s): Trastuzumab-anns
FDA Approved: * June 13, 2019
Pharm Company: * AMGEN INC
Category: Cancer

Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer.[3][4][5][6] It is specifically used for cancer that is HER2 receptor positive.[3] It may be used by itself or together with other chemotherapy medication.[3] Trastuzumab is given by slow injection into a vein and injection just under the skin.[3]&am... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Kanjinti 420 mg/20ml Intravenous Injection, Powder, Lyophilized, for Solution
NDC: 55513-132
Labeler:
Amgen Inc
Kanjinti 150 mg/7.15ml Intravenous Injection, Powder, Lyophilized, for Solution
NDC: 55513-141
Labeler:
Amgen Inc

Related Brands

Drugs with the same active ingredients